Aptus Therapeutics-backed Alzheon has set its pricing range at $13 to $15 and could raise almost $86.3m if underwriters take up their option to purchase additional shares.
Alzheon, a US-based developer of treatments for neurodegenerative disorders backed by pharmaceutical firm Aptus Therapeutics, set its pricing range at $13 to $15 on Monday, putting the potential proceeds at nearly $86.3m.
The company will sell five million shares and has allocated another 750,000 shares to underwriters as an over-allotment option. It will list on the Nasdaq Global Market under the symbol ALZH.
Founded in 2013, Alzheon is developing small molecules that target neurodegenerative disorders such as Alzheimer’s disease…
